FDA approves labeling changes for ED drugs

Share this article:
The FDA has approved some labeling changes to erectile dysfunction drugs— including Viagra, Cialis, and Levitra—to display more prominently an existing risk on the potential for sudden hearing loss. The changes were also made to Pfizer's Revatio, which contains the same active ingredient (sildenafil) as Viagra.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.